Nearly 93% of babies born in Galicia, Spain this fall were given nirsevimab (Beyfortus), the monoclonal antibody that protects against severe RSV, in a clearly successful hospital-based distribution program. US supplies have been severely constrained. www.eurosurveillance.org/content/10.2...